VRAX (Virax Biolabs Group) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRAX Virax Biolabs Group Ltd VRAX
45 GF Score
Price $3.30
GF Value $3.57
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Virax Biolabs Group Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

VRAX vs ISCO, PKTX, GRI: Short Interest Comparison

For the Biotechnology subindustry, Virax Biolabs Group's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Short Interest distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Short Interest falls into.


VRAX
45GF Score
Virax Biolabs Group Ltd VRAX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued. The current stock price of $3.30 is trading 7.6% below its estimated GF Value™ of $3.57. GuruFocus considers Virax Biolabs Group to be Fairly Valued.

Key valuation signals for VRAX:

  • Short Interest:
  • GF Value™: $3.57 vs. price of $3.30 (7.6% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score

Get the complete analysis for VRAX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.30
Price
$3.57
GF Value